Skip to main content
Alvotech Holdings S.A logo

Alvotech Holdings S.A — Investor Relations & Filings

Ticker · ALVO ISIN · LU2458332611 LEI · 222100DCZBOWV5DZ8372 LU Manufacturing
Open in API
Filings indexed 930 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country LU Luxembourg
Listing LU ALVO

About Alvotech Holdings S.A

https://www.alvotech.com/

Alvotech is a biotechnology company that specializes in the development and manufacturing of biosimilar medicines for patients worldwide. The company's mission is to improve lives by expanding access to high-quality, affordable biologic medicines. Alvotech operates a fully integrated, end-to-end platform that encompasses the entire process from cell line development through to fill and finish manufacturing. This vertically integrated approach provides control over scale, speed, and quality. For commercialization and registration in global markets, Alvotech leverages strategic partnerships, allowing it to maintain a singular focus on its core development and manufacturing expertise. The company's product pipeline targets various therapeutic areas, including autoimmune and eye disorders.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 90% confidence The document is a Form 6-K filed by a foreign private issuer reporting regulatory events (FDA acceptance of a BLA, Q1 press releases, interim financial statements) under the Securities Exchange Act. It is not an annual or interim report itself, but a SEC regulatory filing. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-06-08 English
Matvæla- og lyfjastofnun Bandaríkjanna tekur til afgreiðslu umsókn Alvotech um markaðsleyfi fyrir AVT16, fyrirhugaða hliðstæðu við Entyvio
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing that the FDA has accepted Alvotech’s market authorization application for its biosimilar AVT16. It contains no financial statements, no earnings results, no board or management changes, and no investor presentation. It is a general regulatory announcement about product approval steps rather than a formal financial report or specific corporate action. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-06-08 Icelandic
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
Regulatory Filings Classification · 84% confidence The document is a corporate press release announcing the FDA acceptance of a Biologics License Application. It is neither a financial report (annual, interim, earnings release) nor a meeting/material or proxy filing. It is a general regulatory announcement regarding compliance and product approval, fitting the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory updates.
2026-06-08 English
FORM 6-K
Regulatory Filings Classification · 85% confidence The document is a Form 6-K, which is a routine SEC regulatory filing by a foreign private issuer to furnish company announcements (press releases) but does not itself contain substantive financial statements or detailed reports like an annual or interim report. It is not the full annual report or AGM minutes, but rather a compliance submission under the Exchange Act. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-06-04 English
Alvotech leggur inn að nýju umsóknir um markaðsleyfi í Bandaríkjunum fyrir hliðstæður við Simponi, Simponi Aria og Eylea
Regulatory Filings Classification · 80% confidence The document is a company press release announcing that Alvotech has re-submitted applications to the U.S. FDA for biosimilar drug approvals. It contains no financial statements or quantitative results, nor is it a meeting notice or voting announcement. It is a general regulatory update about product approval filings rather than a formal financial report. Under the taxonomy, such miscellaneous regulatory announcements that don’t fit a specific category are classified as Regulatory Filings (RNS).
2026-06-04 Icelandic
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing the resubmission of U.S. Biologics License Applications (BLAs) to the FDA for biosimilar products. It is not an AGM material, financial report, earnings release, management discussion, or share transaction notice. It provides regulatory update information but does not itself constitute an official regulatory filing form like a 10-K or 8-K. It fits the fallback category of general regulatory announcements.
2026-06-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.